| P50 | author | Gregory P. Kalemkerian | Q124968136 |
| | Shirish M Gadgeel | Q124968314 |
| | Antoinette J Wozniak | Q124968320 |
| | Michael J Kraut | Q124968333 |
| P2093 | author name string | Francis P Worden | |
| | Ralph E Parchment | |
| | Rodney L Dunn | |
| | James Zwiebel | |
| | Bryan J Schneider | |
| | Collette M Hodges | |
| P2860 | cites work | Cancer statistics, 2008 | Q27860585 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations | Q28264846 |
| | Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer | Q33328193 |
| | Multidisciplinary management of lung cancer | Q35635254 |
| | Mechanisms of fenretinide-induced apoptosis | Q36540587 |
| | Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study | Q37286891 |
| | Retinoids as preventive and therapeutic anticancer agents (Part I). | Q39760781 |
| | 4-Hydroxyphenylretinamide in the chemoprevention of cancer | Q40380722 |
| | N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. | Q40734731 |
| | Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. | Q40951916 |
| | Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors | Q41267304 |
| | Human lung cancer cell lines exhibit resistance to retinoic acid treatment. | Q42610991 |
| | Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer | Q43543611 |
| | Ceramide signaling in fenretinide-induced endothelial cell apoptosis | Q44185922 |
| | Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. | Q44471521 |
| | Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. | Q44615083 |
| | Fenretinide activates a distinct apoptotic pathway | Q45038671 |
| | Phase II trial of fenretinide in advanced renal carcinoma | Q45296870 |
| | Optimal two-stage designs for phase II clinical trials | Q46412217 |
| | Management of recurrent small cell lung cancer | Q46673346 |
| | Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines | Q48024992 |
| | Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. | Q50756405 |
| | A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. | Q53594187 |
| | N-(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells | Q58813531 |
| | High frequency of retinoic acid receptor beta abnormalities in human lung cancer | Q67701783 |
| | Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells | Q68304765 |
| | Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells | Q69977839 |
| | Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention | Q71365877 |
| | N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid | Q72657599 |
| | Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress | Q73181495 |
| | Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines | Q77922762 |
| | Induction of apoptosis by retinoids in human cervical-carcinoma cell-lines | Q84066253 |
| | Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients | Q93521069 |
| P433 | issue | 6 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| P304 | page(s) | 571-578 | |
| P577 | publication date | 2009-02-19 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer | |
| P478 | volume | 27 | |